Navigation Links
NeuroSigma, Inc. Retains CCG Investor Relations
Date:4/4/2011

LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.

"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.

"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.

Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others.  NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:

Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.

Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.

"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations.  "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the very best at institutions like UCLA and bringing their pioneering work to the marketplace for commercialization.  The Company is initially focused on several very important conditions, including epilepsy, which affects 3 million people in the United States and over 50 million worldwide, and major depression, affecting over 18 million American adults and over 120 million worldwide.  With its current team and strong development processes in place, the Company is well positioned for the future."

About NeuroSigma

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently we have a specific focus on neuromodulation.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed a significant intellectual property portfolio, primarily licensed from the University of California, Los Angeles on a world-wide exclusive basis, including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  More information about NeuroSigma is online at http://www.neurosigma.com/

About CCG Investor Relations

CCG is a leading global investor relations and strategic communications consulting firm.  In business for more than 30 years, the agency provides a complete range of strategic and investor communications, through our global network to over 100 clients across multiple capital markets.  CCG has been awarded a number of industry honors for its handling of complex investor relations communications matters.  The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London, and Tel Aviv.  For further information, contact CCG directly, or visit the Company's web site at http://www.ccgir.com/


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
2. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
3. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
4. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
5. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. Anadys Retains Lazard as Strategic Advisor
8. Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market
9. China Pharma Holdings, Inc. Retains CCG Investor Relations
10. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
11. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):